Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor
- 1 December 2021
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (4) , 380-388
Abstract
Summary: Background: Ustekinumab and vedolizumab are commonly used after anti‐tumour necrosis factor (TNF) failure in patients with Crohn’s disease (CD). No randomised controlled trial has compared these drugs.Aims: To compare the effectiveness of ustekinumab and vedolizumab in CD patients refractory to anti‐TNF.Methods: From PubMed, EMBASE and the Cochrane Library, through March 27, 2021, we identified studies that compared ustekinumab and vedolizumab in patients with CD refractory to anti‐TNF. The main outcomes were clinical remission and steroid‐free clinical remission at weeks 14 and 52. Secondary outcomes were biological remission and treatment persistence. We computed pooled odds ratios (OR) and 95% confidence intervals (CI) using random effects meta‐analysis.Results: We identified 1513 reports. Among them, 38 studies were assessed for eligibility and five studies were included. All studies included were of high quality: four were retrospective and one was prospective. Among 1026 patients, 659 received ustekinumab and 367 received vedolizumab. At week 14, clinical remission (OR 1.36; 95%CI: 0.74‐2.47; I2 = 50%), steroid‐free clinical remission (OR 1.24; 95%CI: 0.79‐1.92; I2 = 52%) and biological remission (OR 0.80; 95%CI: 0.50‐1.28; I2 = 0%) rates were similar between the two treatments. At week 52, ustekinumab was associated with higher rates of clinical remission (OR 1.87; 95% CI: 1.18‐2.98; I2 = 0%), steroid‐free clinical remission (OR 1.56; 95% CI: 1.23‐1.97; I2 = 0%), biological remission (OR 1.86; 95% CI: 1.03‐3.37; I2 = 29%) and treatment persistence (OR 2.37; 95% CI: 1.56‐3.62; I2 = 0%).Conclusion: In patients with CD refractory to anti‐TNF, ustekinumab and vedolizumab are similarly effective in induction, but as maintenance treatment, ustekinumab appears to be more effective than vedolizumab.Keywords
This publication has 29 references indexed in Scilit:
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Therapeutic management of inflammatory bowel disease in real‐life practice in the current era of anti‐TNF agents: analysis of the French administrative health databases 2009–2014Alimentary Pharmacology & Therapeutics, 2016
- Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical managementAlimentary Pharmacology & Therapeutics, 2015
- In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With CautionGastroenterology, 2015
- Optimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Establishing a new journal for systematic review productsSystematic Reviews, 2012
- Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsBMJ, 2011
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohortGut, 2008
- Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2005